Current Scheduling Status
None
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
ECDD Technical summary
Sumatriptan is a 5-HT1-receptor agonist used for the treatment of migraine. Though several cases of abuse, dependence, euphoria, or stupor have been reported as adverse reactions, there is no evidence of significant abuse. The Committee did not recommend sumatriptan for critical review.
Sumatriptan is a 5-HT1-receptor agonist used for the treatment of migraine. Though several cases of abuse, dependence, euphoria, or stupor have been reported as adverse reactions, there is no evidence of significant abuse. The Committee did not recommend sumatriptan for critical review.
ECDD Recommendation
No change in scheduling
Link to full TRS
who_trs_873.pdf4.34 MB